Oppenheimer analyst Michael Wiederhorn raised his price target for UnitedHealth to $300 from $295 following quarterly results. The analyst believes the company remains an industry leader across its various business lines, and has both a diversified and insulated business model that boasts promising growth prospects. He reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.